Company intelligence / Profile preview

Speranza Therapeutics

Boca Raton, Florida, United Statessperanzatherapeutics.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company's flagship product, S.T. Genesis, is an FDA-cleared noninvasive percutaneous nerve field stimulator designed to reduce opioid withdrawal symptoms by targeting specific cranial and occipital nerves via auricular neurostimulation. Clinical results support its use as an effective adjunct for managing acute opioid withdrawal in various treatment settings. No published large-scale clinical trial data was found in the search results.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ST Genesis

Commercial

Indications: Opioid withdrawal

Partnerships

Hygea Healthcare Detox Center integrates S.T. Genesis into their detox program as a partner site.

Beyond the preview

Go deeper on Speranza Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Speranza Therapeutics.